Creating better cancer treatments using antibody drug conjugates
Designing Antibody Drug Conjugates for Durable and Complete Therapeutic Responses
['FUNDING_OTHER'] · UNIVERSITY OF MICHIGAN AT ANN ARBOR · NIH-11005407
This study is looking at how to make cancer treatments called antibody drug conjugates (ADCs) work better by understanding how they interact with the immune system, which could help improve outcomes for patients with solid tumors.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MICHIGAN AT ANN ARBOR (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-11005407 on ClinicalTrials.gov |
What this research studies
This research focuses on improving antibody drug conjugates (ADCs), which are innovative cancer treatments that combine antibodies with drugs to target and kill cancer cells. The study investigates how these ADCs interact with the immune system to enhance their effectiveness, particularly in solid tumors. By exploring the mechanisms of action and the immune responses triggered by ADCs, the research aims to identify optimal designs and combinations of therapies that can lead to better patient outcomes. Patients may benefit from insights that could lead to more effective cancer treatments in the future.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with solid tumors who may benefit from advanced cancer therapies.
Not a fit: Patients with non-cancerous conditions or those not diagnosed with solid tumors may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and durable cancer treatments that improve patient survival rates.
How similar studies have performed: Previous research has shown promising results with antibody drug conjugates, indicating potential for significant advancements in cancer treatment.
Where this research is happening
ANN ARBOR, UNITED STATES
- UNIVERSITY OF MICHIGAN AT ANN ARBOR — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: THURBER, GREG — UNIVERSITY OF MICHIGAN AT ANN ARBOR
- Study coordinator: THURBER, GREG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anticancer immunotherapy, cancer immunotherapy, Cancers